Latest Videos

The presented work deals with the development of a fragment based strategy for dual-target drug discovery.

Simon Ward, University of Sussex, speaking at Discovery Chemistry Congress 2015

Seth Crosby, Washington University School of Medicine, discusses both bench and informatic methods used to increase specificity in the apprehension of rare cfDNA alleles.

Jeff Cummings presents a worked example of circulating tumour cell enumeration as a prognostic/predictive biomarker in cancer research.

Metabolomics has been successfully applied to identify and validate biomarkers for congestive heart failure. Diagnosis and risk stratification of heart failure (HF) is challenging.

Amol Kulkarni, National Chemical Laboratory, speaking at Flow Chemistry India.

Jutta Eichler, University of Erlangen-Nuremberg, speaking at Discovery Chemistry Congress 2015.

There is often a debate about just how useful fragments are for well-established conventional targets such as protein kinases. Fragment screening however can be extremely valuable, providing critical ideas that lead to novelty, demonstrating how to achieve selectivity, helping dissect and make the most of HTS and literature compounds, alongside maximising ligand efficiency.

Asier Unciti-Broceta, University of Edinburgh, speaking at Discovery Chemistry Congress 2015.

Targeted mass spectrometry, called MRM or SRM, allows for the rapid quantification of hundreds of proteins in a single assay. This tool is very specific, highly quantitative and requires very little sample (e.g. < 5 uL plasma).